Akebia Therapeutics
AKBA
145 hedge funds and large institutions have $536M invested in Akebia Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 28 closing their positions.
1,259% more call options, than puts
Call options by funds: $9M | Put options by funds: $662K
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
30% more capital invested
Capital invested by funds: $412M → $536M (+$124M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.94% less ownership
Funds ownership: 77.36% → 75.42% (-1.9%)
5% less funds holding
Funds holding: 153 → 145 (-8)
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$11.4M |
| 2 |
BlackRock
New York
|
+$7.18M |
| 3 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$4.95M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.31M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.6M |
| 2 |
Renaissance Technologies
New York
|
-$6.45M |
| 3 |
Goldman Sachs
New York
|
-$4.74M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$4.47M |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$3.14M |
AKBA Hedge Fund Activity: Q2 2018 in Review
145 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2018, worth a combined $536M — up 30% from $412M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of AKBA and 20 opened new positions — a net loss of 8 holders — while 39 trimmed existing stakes and 57 added.
The largest buyer was Nantahala Capital Management, adding an estimated $11.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.6M sold.
- 145 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2018, down from 153 in Q1 2018.
- Funds reported $536M of Akebia Therapeutics stock for Q2 2018, up 30% quarter-over-quarter.
- 20 funds opened new Akebia Therapeutics positions in Q2 2018 and 28 closed out, a net change of -8 holders.
- The largest Akebia Therapeutics buyer in Q2 2018 was Nantahala Capital Management, an estimated $11.4M added.
- The largest Akebia Therapeutics seller in Q2 2018 was EcoR1 Capital, an estimated $13.6M sold.
Based on aggregated 13F filings for Q2 2018.